On August 20, 2024, Steve Miller, Chief Operating & Scientific Officer of Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), sold 150,000 shares of the company. The transaction was documented in a recent SEC filing. After this sale, the insider now owns 675,124 shares of the company.

Catalyst Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases.

Over the past year, the insider has sold a total of 190,000 shares and purchased no shares. This recent sale is part of a broader trend seen at Catalyst Pharmaceuticals Inc., where there were 14 insider sales and no insider purchases over the past year.

Catalyst Pharmaceuticals Inc. shares were trading at $20.35 on the day of the sale. The company has a market capitalization of around $2.46 billion. The stock’s price-to-earnings ratio is 38.41, which is higher than both the industry median of 25.66 and the company’s historical median.

The GF Value of the stock is estimated at $19.79, resulting in a Price to GF Value ratio of 1.03, indicating that the stock is fairly valued.

The GF value is calculated by taking into account historical trading multiples such as price-to-earnings ratio, price-to-sales ratio, price-to-book ratio and price-to-free cash flow, along with a GuruFocus adjustment factor based on past earnings and growth as well as Morningstar analysts’ views on future business performance.

This insider sale at Catalyst Pharmaceuticals Inc. provides an interesting data point for investors who track insider behavior and company stock valuation.

This article created by GuruFocus is intended to provide general insights and does not constitute tailored financial advice. Our commentary is based on historical data and analyst forecasts, uses an unbiased methodology and is not intended to serve as specific investment advice. It does not contain a recommendation to buy or sell any stock and does not take into account any individual investment objectives or financial circumstances. Our goal is to provide long-term, fundamental, data-driven analysis. Note that our analysis may not include the most recent, price-sensitive company announcements or qualitative information. GuruFocus does not hold a position in any stocks mentioned here.

This article first appeared on GuruFocus.